Poor Man, it sounds like you are saying that NWBio would purchase Advent so NWBio can make money off of its contract with Advent, to manufacture DCVax-L.
That sounds like circular reasoning and it does not make any sense.
I cannot decipher much meaning from your posts. They really are confused and misguided statements.
The value of this cell-based immunotherapy platform technology will be determined by the integrity of the science, and the regulatory process will be the catalyst.
The leadership of the company are capable and focused. While I am more fascinated by the science side of the story, there is a lot of fascinating history and background with regard to the business and management side too. It is notable to discover the level of talent and experience of those who have committed years to the company as its leadership team. They are not young and each has a long personal history of education and experience leading to wisdom and wealth.
Research the backgrounds of the leadership team and form your own opinion based on verifiable information.
Market Data 
Markets 
AI
